Celeste Krewson, Assistant Editor

In a recent study, a significant improvement in the average quality-adjusted life years gained was reported following BRCA1 testing during obstetrical prenatal carrier screening.

A recent study shows that adding metronidazole to cefazolin significantly lowers the risk of surgical site infections in gynecologic cancer surgeries, enhancing patient outcomes.

In a recent study, very preterm birth rates were reduced during COVID-19 lockdown periods vs prepandemic periods.

In a recent study, reported rates on emergency department utilization for hypertensive disorders of pregnancy and the postpartum period were higher in 2020 than 2006, with rates especially high among non-Hispanic Black, Hispanic, and Asian patients.

Learn how self-advocacy, preparation, and collaboration with doctors can help women gain control over their health and live more fully, free from stigma and shame.

Discover how deepening understanding and providing vetted resources can empower women to reclaim their wellness and navigate the powerful impacts of menopause with confidence.

New research shows fezolinetant significantly reduces the frequency and severity of hot flashes in Hispanic women, offering a safer alternative to hormone replacement therapy.

Fezolinetant offers women a groundbreaking, non-hormonal solution to manage menopause symptoms like hot flashes and sleep disturbances, supported by large clinical trials.

A new study highlights gestational hypertension as a significant predictor of cardiovascular disease in menopausal women, challenging previous assumptions about preeclampsia’s role.

Research reveals that environmental exposures and PTSD from Gulf War service significantly increase the likelihood of early menopause, highlighting the need for targeted reproductive health care for women veterans.

Vanessa Muñiz presents research comparing clinical hypnosis and cognitive behavioral therapy for treating hot flashes, revealing that hypnosis significantly reduces frequency and improves quality of life.

At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.

The phase 3 OASIS trial presented at the 2024 Annual Meeting of The Menopause Society displayed significant improvements in the frequency of moderate-to-severe vasomotor symptoms among patients receiving elinzanetant.

Low rates of hormone therapy use have been reported among midlife women, stagnating after decreases in the immediate aftermath of the Women’s Health Initiative.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, insulin resistance was significantly reduced among postmenopausal women receiving hormone therapy vs placebo.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, 23% of patients with breast arterial calcifications on a mammogram had atherosclerotic cardiovascular disease, vs 13.9% without.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, the prevalence of Alzheimer’s disease was significantly increased among women with prior trauma.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, women with certain adverse outcomes during pregnancy had an increased risk of cardiovascular disease later in life.

Amanda Williams, MD, MPH, FACOG, Interim Chief Medical Officer at March of Dimes, discusses the reported increase in the number of US counties with no obstetric care providers.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, 59% of nocturnal hot flashes occurred during the second half of the night, a time linked to increased cardiovascular disease risk.

Data presented at the 2024 Annual Meeting of The Menopause Society highlighted greater reductions in hot flash severity among women receiving clinical hypnosis compared to those receiving cognitive behavioral therapy.

In a recent study, women with urinary incontinence were more likely to experience postpartum depression at both under and over 6 months after delivery.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

The advisory committee meeting will discuss the potential approval of oral sulopenem etzadroxil/probenecid tablets for treating urinary tract infections in women aged 18 years and older.

In a recent study, neurodevelopmental outcomes did not significantly differ among children exposed to metformin in utero vs those unexposed.

In a recent study, women with higher levels of per- and polyfluoroalkyl substances during pregnancy reported increased weight and body fat later in life.

The new single-handed inserter by CooperSurgical streamlines the placement of Paragard, a hormone-free IUD with over 30 years of proven efficacy, enhancing accessibility for both health care providers and patients.

In a recent study, rates of 12-month or longer contraceptive supply were increased by the implementation of a 12-month contraceptive supply policy.

In a recent study, the odds of adverse pregnancy outcomes were significantly increased in pregnancies of women with solid organ transplants.

In a recent study, reduced aging discrepancies were observed in postmenopausal women reporting hormone therapy use vs nonusers.